Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients |
Type de publication | Journal Article |
Year of Publication | 2020 |
Auteurs | Gouin A, Sberro-Soussan R, Courivaud C, Bertrand D, Del Bello A, Darres A, Ducloux D, Legendre C, Kamar N |
Journal | KIDNEY INTERNATIONAL REPORTS |
Volume | 5 |
Pagination | 2195-2201 |
Date Published | DEC |
Type of Article | Article |
ISSN | 2468-0249 |
Mots-clés | belatacept, calcineurin inhibitor, conversion, donor-specific antibody, kidney function, Safety |
Résumé | {Introduction: During the coronavirus disease 2019 (Covid-19) pandemic, several physicians have questioned pursuing belatacept in kidney-transplant patients in order to reduce the risk of nosocomial transmission during the monthly infusion. The effect of the conversion from belatacept to another immunosuppressive regimen is underreported. The aim of the present retrospective study was to assess the effect on kidney function and the clinical outcome of the conversion from belatacept to another regimen. Methods: We have identified 44 maintenance kidney transplantation patients from five French kidney transplantation centers who were converted from belatacept to another regimen either because of a complication (n = 28) or another reason (patients' request or belatacept shortage |
DOI | 10.1016/j.ekir.2020.09.036 |